课题基金 / 基金详情

Determination of HIV Drug Resistance Among Children and Mothers Enrolled in Progr

Determination of HIV Drug Resistance Among Children and Mothers Enrolled in Progr
参与计划的儿童和母亲的艾滋病毒耐药性测定
批准号:
8460402
负责人:
ACHIANGIA PATRICK NJUKENG
金额:
$40.77万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-30 至 2015-09-29

项目摘要

项目成果

ACHIANGIA PATRICK NJUKENG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Abstract / Summary. In Cameroon the HIV epidemic is generalized with an estimated prevalence of 5.1%, and characterized by a very high genetic diversity. Indeed, to date the epidemic is driven by all HIV subtypes including circulating recombinant forms (CRF), unique recombinant forms (URF), and highly divergent strains such as groups O, and N and P. The impact of the high diversity on the emergence of HIV drug resistance in Cameroon has not been well studied. In 2010, the coverage of the PMTCT was 22.2% with 16.0% of infected children receiving antiretroviral treatment nationwide. Limited studies in Cameroon reported primary resistance-associated mutations among antiretroviral therapy (ART) drug-na¿ve persons, mainly to reverse transcriptase (RT) and protease inhibitors. The Cameroon Baptist Convention Health Board (CBCHB) currently supports 427 sites all over the country for the Prevention of Mother-to-Child Transmission (PMTCT) program, of which 240 are government facilities. To date, CBCHB has counseled 450, 231 women and tested 428, 370 (95.1%) at these facilities (with an HIV prevalence of 10.7%). Thanks largely to the CBCHB efforts, maternal and infant ART uptake rates have increased in Cameroon from 37.7% in 2000 to 96.6% in 2009. The goal of this study is to determine the prevalence of drug-resistant HIV among children < 18 months of age, and also evaluate the impact of the enormous HIV genetic diversity on the occurrence of drug-resistant mutations in PMTCT programs in Cameroon. Leftover dried blot spot specimens collected originally for early infant diagnosis will be used in this study. The outcome of this study will assist decision-making on first-line antiretroviral drug regimens for the PMTCT program in Cameroon and will provide a better understanding of the association of the extensive HIV genetic diversity and occurrence of resistant mutations. It will also contribute to the global effort to respond to the emergence of HIV drug resistance.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GH12-008, Cameroon, Determination of HIV Drug Resistance Among Children and Mothers Enrolled in Progr
  • 批准号:
    8827179
  • 项目类别:
  • 资助金额:
    $0.5万
  • 财政年份:
    2013
  • 负责人:
    ACHIANGIA PATRICK NJUKENG
  • 依托单位:
GH12-008, Cameroon, Determination of HIV Drug Resistance Among Children and Mothers Enrolled in Progr
  • 批准号:
    9071613
  • 项目类别:
  • 资助金额:
    $62.73万
  • 财政年份:
    2013
  • 负责人:
    ACHIANGIA PATRICK NJUKENG
  • 依托单位:
国内基金
海外基金
人类免疫缺陷病毒(HIV)总核酸检测试剂盒
HIV相关肺癌免疫微环境中关键免疫细胞亚群的功能特征与调控机制研究
基于深度测序与SNV 芯片的HIV重复感染与毒株重组机制研究
  • 批准号:
    2026JJ81281
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    徐艳
  • 依托单位:
PGT123中和抗体修饰的工程化载肽囊泡疫苗通过诱导CD4+ T细胞极化在抗HIV感染中的应用和机制研究